Summary of exposure by population
| Population | No of studies | Salmeterol-containing product | Comparator | ||
| No of subjects | Total exposure (years) | No of subjects | Total exposure (years) | ||
| Salmeterol-containing product vs non-LABA | 215 | 57607 | 20573 | 48968 | 18433 |
| Salmeterol vs placebo (without ICS) | 54 | 9463 | 3787 | 8932 | 3682 |
| Salmeterol + ICS (BK/RD)* vs ICS (BK/RD)* | 127 | 24542 | 10285 | 24173 | 10243 |
| Fluticasone/salmeterol combination (RD)† vs ICS (RD)† | 63 | 11437 | 5020 | 11163 | 5008 |
*BK/RD, ICS received as background medication or as randomised study drug.
†RD, ICS received as randomised study drug.
ICS, inhaled corticosteroid; LABA, long-acting β agonist.